ARIAD Pharmaceuticals, Inc. (ARIAD) is a global oncology company focused on the discovery, development and commercialization of medicines for the cancer patients. ARIAD's first medicine, Iclusig, is approved in the United States for the treatment of adult patients with chronic, accelerated or blast phase chronic myeloid leukemia that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia that is resistant or intolerant to prior TKI therapy. As of January 11, 2013, additional clinical trials of Iclusig in other cancers were ongoing. As of January 11, 2013, ARIAD also studied AP26113, another molecularly targeted medicine, in certain forms of lung cancer.
|Headquarters||26 Landsdowne Street|
CAMBRIDGE, MA, United States 02139-4234
|Chairman of the Board, President, Chief Executive Officer||Harvey Berger|
|Chief Financial Officer, Executive Vice President, Treasurer||Edward Fitzgerald|
|Senior Vice President, General Counsel, Secretary and Chief Compliance Officer||Raymond Keane|
|Senior Vice President, Chief Intellectual Property Officer||David Berstein|
|Senior Vice President - Regulatory Affairs and Quality||Daniel Bollag|
With TD Waterhouse, you have access to the industry's leading selection of independent research reports from providers such as TDSI, TD Securities, S&P, INK and Argus.
|Shares Out.||184.7M||Book Value||$0.68|
|Annual Dividend Rate||$0.00||Price/Sales (TTM)||473.2|
|Ex-Div Date||1/1/01||P/Cash Flow (TTM)||--|
|Pay Date||1/1/01||Operating Margin||-3,308.28%|
*GAAP = prior to non-GAAP analyst adjusted earnings.